LYNBROOK, N.Y., Sept. 14 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming UBS Global Life Sciences Conference on Monday, September 20, 2010, at 7:30am ET at the Grand Hyatt New York in New York City.
A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at http://www.biospecifics.com, or you may use the link: http://cc.talkpoint.com/ubsx001/092110a_lv/?entity=130_6627G0J.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for eleven clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium markets XIAFLEX in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAFLEX in Europe. More information about BioSpecifics may be found on its website at http://www.biospecifics.com.
SOURCE BioSpecifics Technologies Corp.